KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Gross Profit: 2011-2025

Historic Gross Profit for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $163.3 million.

  • Travere Therapeutics' Gross Profit rose 166.47% to $163.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $425.5 million, marking a year-over-year increase of 119.67%. This contributed to the annual value of $225.4 million for FY2024, which is 68.50% up from last year.
  • As of Q3 2025, Travere Therapeutics' Gross Profit stood at $163.3 million, which was up 44.58% from $112.9 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Gross Profit peaked at $163.3 million during Q3 2025, and registered a low of $13.1 million during Q4 2021.
  • Moreover, its 3-year median value for Gross Profit was $52.1 million (2024), whereas its average is $64.8 million.
  • Per our database at Business Quant, Travere Therapeutics' Gross Profit crashed by 73.28% in 2021 and then surged by 166.47% in 2025.
  • Travere Therapeutics' Gross Profit (Quarterly) stood at $13.1 million in 2021, then spiked by 117.83% to $28.5 million in 2022, then surged by 42.23% to $40.5 million in 2023, then spiked by 78.38% to $72.2 million in 2024, then spiked by 166.47% to $163.3 million in 2025.
  • Its Gross Profit stands at $163.3 million for Q3 2025, versus $112.9 million for Q2 2025 and $77.1 million for Q1 2025.